For psoriasis, molecular signature in healthy-appearing skin may be best predictor of response to anti-TNF treatment

It’s common for people with psoriasis to develop dry, inflamed skin lesions. But researchers found specific gene expression changes in healthy-appearing skin were a better predictor of clinical response to etanercept, an anti-TNF treatment prescribed to up to one-fifth of psoriasis patients. They say finding predictive signs in a patient’s genetic profile is a step toward applying precision medicine to complex inflammatory skin diseases.